All In Biotech

Drug Trial Radar · NCT02032524

Avalglucosidase Alfa Extension Study

An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety and Pharmacokinetics of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) in Patients With Pompe Disease

Last checked: Nov 20, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Feb 27, 2014

Primary completion

Dec 12, 2022

Study completion Dec 12, 2022

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Long-term safety and pharmacokinetics (PK) of avalglucosidase alfa Secondary Objective: Long-term effect of avalglucosidase alfa on pharmacodynamic variables

Conditions

  • Glycogen Storage Disease Type II Pompe Disease

Interventions

  • Avalglucosidase AlfaDrug

    Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Infusion Associated Reactions (IARs) and DeathsTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  2. Number of Participants With Clinically Significant Physical Examination AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  3. Number of Participants With Potentially Clinically Significant Abnormalities in BiochemistryTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  4. Number of Participants With Potentially Clinically Significant Abnormalities in HematologyTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  5. Change From Baseline in Urine BUN up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
  6. Change From Baseline in Urine Hyaline Casts up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
  7. Change From Baseline in Urine Leukocytes [White Blood Cell (WBC)] up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
  8. Change From Baseline in Urine Specific Gravity up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
  9. Change From Baseline in Urine pH up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
  10. Number of Participants With Potentially Clinically Significant Vital Signs AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  11. Number of Participants With Body Weight Increased/DecreasedTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  12. Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  13. Number of Participants With Antidrug Antibodies (ADA) Status, Positive or NegativeTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
  14. Maximum Observed Plasma Concentration (Cmax) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
  15. Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Real Time (AUClast) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
  16. Time Corresponding to the Last Concentration (Tlast) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
  17. Terminal Half-Life (t1/2z) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
  18. Apparent Total Body Clearance Steady-State (CLss) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
  19. Apparent Volume of Distribution Steady-State (Vss) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840006

    Phoenix, Arizona

  • Investigational Site Number 840010

    Jacksonville, Florida

  • Investigational Site Number 840001

    Kansas City, Kansas

  • Investigational Site Number 840008

    St Louis, Missouri

  • Investigational Site Number 840002

    Durham, North Carolina

  • Investigational Site Number 840011

    Cincinnati, Ohio

  • Investigational Site Number 840009

    Dallas, Texas

  • Investigational Site Number 840003

    Fairfax, Virginia

  • Investigational Site Number 056001

    Leuven, Belgium

  • Investigational Site Number 208001

    København Ø, Denmark

  • Investigational Site Number 250003

    Nice, France

  • Investigational Site Number 250002

    Paris, France

  • Investigational Site Number 276003

    Mainz, Germany

  • Investigational Site Number 276001

    München, Germany

  • Investigational Site Number 276002

    Münster, Germany

  • Investigational Site Number 528001

    Rotterdam, Netherlands

  • Investigational Site Number 826003

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.